TABLE 2.
Substitutions in CA-CYP51 resulting in azole resistance in clinical C. albicans isolates
| Patient and isolate | MIC (μg/ml)
|
Substitutions in CA-CYP51 | |||
|---|---|---|---|---|---|
| POS | FLZ | ITZ | VOR | ||
| C43c | 0.03 | 0.125 | 0.06 | 0.03 | None (azole-sensitive reference strain) |
| Ia | |||||
| C438 | 0.5 | 128 | 0.5 | 2 | Tyr257His, Gly464Ser |
| C439 | 1 | >256 | 4 | 16 | Tyr257His, Gly464Ser, Gly307Ser |
| C440 | 4 | >256 | 8 | >16.0 | Tyr257His, Gly464Ser, Gly307Ser, Ala61Val |
| IIb | |||||
| C369 | 0.25 | 32 | 1 | 4 | Lys128Thr, Tyr132His, Asp278Asn, Gly464Ser |
| C375 | 2 | 48 | 16 | 4 | Lys128Thr, Tyr132His, Asp278Asn, Gly464Ser, Pro230Leu |
a
MICs and data on mutations from A. Chau et al., unpublished data.
b
MICs and data on mutations from reference 10a.
c
Reference strain (not a patient isolate).